In this response to Robert Hudson’s article, “Should We Strive to Make Science Bias-Free? A Philosophical Assessment of the Reproducibility Crisis,” we identify three ways in which he misrepresents our work: he conflates value-ladenness with bias; he describes our view as one in which values are the same as evidential factors; and he creates a false dichotomy between two ways that values could be considered in science for policy. We share Hudson’s concerns about promoting scientific reproducibility and reducing bias in (...) science, but we reject his view that the value-free ideal provides helpful guidance for addressing these issues. (shrink)

"Why should we care about having true beliefs? And why do demonstrably false beliefs persist and spread despite consequences for the people who hold them? Philosophers of science Cailin O’Connor and James Weatherall argue that social factors, rather than individual psychology, are what’s essential to understanding the spread and persistence of false belief. It might seem that there’s an obvious reason that true beliefs matter: false beliefs will hurt you. But if that’s right, then why is it irrelevant to many (...) people whether they believe true things or not? In an age riven by "fake news," "alternative facts," and disputes over the validity of everything from climate change to the size of inauguration crowds, the authors argue that social factors, not individual psychology, are what’s essential to understanding the persistence of false belief and that we must know how those social forces work in order to fight misinformation effectively."–Publisher’s description. (shrink)

Solving the “new demarcation problem” requires a distinction between epistemically legitimate and illegitimate roles for non-epistemic values in science. This paper addresses one ‘half’ (i.e. a sub-problem) of the new demarcation problem articulated by the Gretchenfrage: What makes the role of a non-epistemic value in science epistemically illegitimate? I will argue for the Explaining Epistemic Errors (EEE) account, according to which the epistemically illegitimate role of a non-epistemic value is defined via an explanatory claim: the fact that an epistemic agent (...) is motivated by a non-epistemic value explains why the epistemic agent commits a particular epistemic error. The EEE account is inspired by Douglas’ and Steel’s “functionalist” or “epistemic constraint” accounts of epistemic illegitimacy. I will suggest that the EEE account is able to meet two challenges that these two accounts face, while preserving the key intuition underlying both accounts. If my arguments succeed, then the EEE account provides a solution to one half of the new demarcation problem (by providing a definition of what makes the role of a non-epistemic value epistemically illegitimate) and it opens up new ways for addressing the other half (i.e. characterizing an epistemically legitimate role for non-epistemic values). (shrink)

In recent years, industry-funded research has come under fire because of concerns that it can be biased in favor of the funders. This article suggests that efforts by philosophers of science to analyze the concept of objectivity can provide important lessons for those seeking to evaluate and improve industry-funded research. It identifies three particularly relevant criteria for objectivity: transparency, reproducibility, and effective criticism. On closer examination, the criteria of transparency and reproducibility turn out to have significant limitations in this context, (...) but the criterion of effective criticism suggests some important strategies for improving the objectivity of industry-funded science. (shrink)

“Female sexual dysfunction” is the type of contested disease that has sparked concern about the role of the pharmaceutical industry in medical science. Many policies have been proposed to manage industry influence without carefully evaluating whether the proposed policies would be successful. We consider a proposal for incorporating citizen stakeholders into scientific research and show, via a detailed case study of the pharmaceutical regulation of flibanserin, that such programs can be co-opted. In closing, we use Holman’s asymmetric arms race framework (...) as a tool for evaluating policies in industry-funded science. (shrink)

The growing commercialization of scientific research has raised important concerns about industry bias. According to some evidence, so-called industry bias can affect the integrity of the science as well as the direction of the research agenda. I argue that conceptualizing industry’s influence in scientific research in terms of bias is unhelpful. Insofar as industry sponsorship negatively affects the integrity of the research, it does so through biasing mechanisms that can affect any research independently of the source of funding. Talk about (...) industry bias thus offers no insight into the particular epistemic shortcomings at stake. If the concern is with the negative effects that industry funding can have on the research agenda, conceptualizing this influence as bias obscures the ways in which such impact is problematic and limits our ability to offer solutions that can successfully address the concerns raised by the growing role of private funding in science. (shrink)

The US Food and Drug Administration (FDA) is fraught with controversies over the role of values and politics in regulatory science, especially with drugs in the realm of reproductive health. Philosophers and science studies scholars have investigated the ways in which social context shapes medical knowledge through value judgments, and feminist scholars and activists have criticized sexism and injustice in reproductive medicine. Nonetheless, there has been no systematic study of values and gender norms in FDA drug regulation. I focus on (...) three questions about values in regulatory science. First, how have societal values and gender norms shaped the way that the FDA regulates drugs in the realm of reproductive health, specifically with drug labels? Second, what are the ethical, epistemic, and social consequences of these influences on regulation for women and other marginalized groups? Third, which societal values and gender norms ought to influence drug regulation about reproductive health, and how ought this happen? Integrating philosophical analysis with historical archival research and in-depth interviews, I conduct three case studies of drug labeling about reproductive health: (1) the “drug fact” about the mechanism of the morning-after pill; (2) the package inserts for patients about the health risks of oral contraceptives; and (3) the special physician labels made for prescribing drugs to pregnant women. I identify three challenges for the FDA and suggest ways to reduce the influence of sexist values and facilitate feminist alternatives. First, across these cases, I have found that there are many ways in which other concerns in reproductive medicine (such as zygotic life, fetal health, and population control) have devalued women’s health. Second, both knowledge and ignorance xvi about their reproductive health have contributed to women’s oppression, especially poor women and women of color. Finally, by avoiding the epistemic dimensions of ethics, powerful, mostly male parties in medicine (such as doctors, pharmaceutical companies, and religious institutions) have misused “informed consent,” “religious freedom,” and “paternalism” for unethical purposes. For improvement, I suggest extracting sexist values and gender norms from regulatory science that cause epistemic injustices, and I point to success stories for reforming sexism with feminism at the FDA. (shrink)

Biased research occurs frequently in the sciences. In this paper, I will focus on one particular kind of biased research: research that is subject to sponsorship bias. I will address the following epistemological question: what precisely is epistemically wrong with biased research of this kind? I will defend the evidential account of epistemic wrongness: that is, research affected by sponsorship bias is epistemically wrong if and only if the researchers in question make false claims about the evidential support of some (...) hypothesis H by data E. I will argue that the evidential account captures the epistemic wrongness of three paradigmatic types of sponsorship bias. (shrink)

Although the impact of so-called “sponsorship bias” has been the subject of increased attention in the philosophy of science, what exactly constitutes its epistemic wrongness is still debated. In this paper, I will argue that neither evidential accounts nor social–epistemological accounts can fully account for the epistemic wrongness of sponsorship bias, but there are good reasons to prefer social–epistemological to evidential accounts. I will defend this claim by examining how both accounts deal with a paradigm case from medical epistemology, recently (...) discussed in a paper by Bennett Holman. I will argue that evidential accounts cannot adequately capture cases of sponsorship bias that involve the manufacturing of certainty because of their neutrality with respect to the role of non-epistemic values in scientific practice. If my argument holds, it further highlights the importance of integrating social and ethical concerns into epistemological analysis, especially in applied contexts. One can only properly grasp sponsorship bias as an epistemological problem if one resists the methodological tendency to analyze social, ethical, and epistemological issues in isolation from each other. (shrink)

Is Translational Science and Medicine new? Its dramatic expansion has spelled a dizzying array of new disciplines, departments, buildings, and terminology. Yet, without novel theories or concepts, Translational Science and Medicine may appear to be nothing more than an old concept with a new brand. Yet, is this view true? As is illustrated herein, histories of TSM which treat it as merely an old product under a new name misunderstand its essential architecture. As an expressly economic transformation, modern translational approaches (...) are differentiated precisely by a set of semi-permanent architectures which render it an altogether different kind of object when compared to previous attempts by institutions to turn science into medicine. Powered by new software, embedded within campuses that now house companies, and with legal agreements that outline agreed-upon scientific activity, TSM is now powered by a set of robust and durable structures that differentiate it from previous approaches. Based on ethnographic research about translational neuroscience in North America, this paper suggests that the sense of TSM as not being new is a consequence of analytic modes that tend to see scientific enterprises in epistemic terms alone. Analyzing TSM as primarily a scientific object misses the fact that it is a principally a financial one. (shrink)

In recent years, philosophers of science have taken renewed interest in pursuing scholarship that is “socially engaged.” As a result, this scholarship has become increasingly relevant to public policy. In order to illustrate the ways in which the philosophy of science can inform public policy, this chapter focuses specifically on environmental research and policy. It shows how philosophy can assist with environmental policy making in three ways: clarifying the roles of values in policy-relevant science; addressing scientific dissent, especially in response (...) to “hot-button” policy issues; and responding thoughtfully to scientific uncertainty. (shrink)

This response addresses the excellent responses to my book provided by Heather Douglas, Janet Kourany, and Matt Brown. First, I provide some comments and clarifications concerning a few of the highlights from their essays. Second, in response to the worries of my critics, I provide more detail than I was able to provide in my book regarding my three conditions for incorporating values in science. Third, I identify some of the most promising avenues for further research that flow out of (...) this interchange. (shrink)